Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0HI1K
|
|||
| Former ID |
DCL000384
|
|||
| Drug Name |
GSK618334
|
|||
| Synonyms |
Fingolimod hydrochloride; 162359-56-0; FTY720; Fingolimod HCl; Gilenya; Gilenia; Fty-720; Fty 720; Fingolimod (FTY720) HCl; Fingolimod (hydrochloride); 2-Amino-2-(4-octylphenethyl)propane-1,3-diol hydrochloride; 2-Amino-2-(2-(4-octylphenyl)ethyl)-1,3-propanediol hydrochloride; UNII-G926EC510T; Fingolimod hydrochloride [USAN]; CHEBI:63112; G926EC510T; 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol hydrochloride; AK-33554; 2-AMINO-2-[2-(4-OCTYL-PHENYL)-ETHYL]-PROPANE-1,3-DIOL HCL; Fingolimod-d4 Hydrochloride
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Drug abuse [ICD-11: 6C4G.1Z; ICD-10: F19] | Phase 1 | [1] | |
| Nasopharyngeal carcinoma [ICD-11: 2B6B; ICD-9: 147] | Investigative | [2] | ||
| Company |
GSK
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C19H34ClNO2
|
|||
| Canonical SMILES |
CCCCCCCCC1=CC=C(C=C1)CCC(CO)(CO)N.Cl
|
|||
| InChI |
1S/C19H33NO2.ClH/c1-2-3-4-5-6-7-8-17-9-11-18(12-10-17)13-14-19(20,15-21)16-22;/h9-12,21-22H,2-8,13-16,20H2,1H3;1H
|
|||
| InChIKey |
SWZTYAVBMYWFGS-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 162359-56-0
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
10234529, 12014880, 14900483, 26758737, 44436887, 47206133, 50021117, 53600034, 53800768, 57338355, 85171085, 92719820, 98528441, 99300584, 99436939, 103669455, 104380162, 109692984, 117672600, 118842531, 124757869, 124772071, 125164672, 125342329, 126522748, 126628080, 126648547, 126666984, 126731322, 134339028, 134339285, 134964386, 135066165, 135727426, 136345852, 136367507, 136367937, 136920394, 136964585, 137065890, 143493393, 144115996, 152233650, 152258330, 160647169, 162011674, 162037993, 162185346, 163378868, 163688106
|
|||
| ChEBI ID |
CHEBI:63112
|
|||
| ADReCS Drug ID | BADD_D00899 | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT00513279) To Investigate If Single Doses Of GSK618334 Are Safe And To Investigate Blood Levels Of GSK618334. U.S. National Institutes of Health. | |||
| REF 2 | Sphingosine kinase 1 is a potential therapeutic target for nasopharyngeal carcinoma.Oncotarget. 2016 Dec 6;7(49):80586-80598. | |||
| REF 3 | Clinical pipeline report, company report or official report of GlaxoSmithKline (2009). | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.